A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...
– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers ...
Antibody drugs that go after two targets have already made their mark in blood cancers, but the field is working to improve on the safety and efficacy of this approach. Merck is getting a contender ...
Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, ...
Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives. AZD0486 is a novel IgG ...
Title: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) ...
The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space. The future treatment landscape for ...
The U.S. Food and Drug Administration (FDA) cleared the investigational new drug application for Cullinan Therapeutics’ CLN-978 for the treatment of systemic lupus erythematosus (SLE). Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results